[DRP] - I L - Atezolizumab/Durwalumab 04.2025 [MIĘDZYBŁONIAK] Niwolumab+Ipiliumab 04.2025 [NDRP] - ADIUWANT - ALK 04.2025 [NDRP] - ADIUWANT - Atezolizumab 04.2025 [NDRP] - ADIUWANT - Ozymertynib 04.2025 [NDRP] - I L - immunoterapia +/- chemioterapia 04.2025 [NDRP] - I L - Afatynib/Ozymertynib 04.2025 [NDRP] - II+ L - Nintendanib + chemioterapia 04.2025 [NDRP] - II+ L - Ozymertynib 04.2025 [NDRP] - II+ L - Sotorasib 04.2025 [NDRP] - II+L - Atezolizumab/Niwolumab 04.2025 [NDRP] - KONSOLIDACJA - Durwalumab 04.2025 [NDRP] - NEOADIUWANT - Nivolumab + chemioterapia 04.2025 [NDRP] - PALIATYWNE - ALK/ROS-1 04.2025